Zosano Pharma Corporation (ZSAN): Price and Financial Metrics


Zosano Pharma Corporation (ZSAN): $0.42

-0.01 (-3.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZSAN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

ZSAN POWR Grades


  • ZSAN scores best on the Growth dimension, with a Growth rank ahead of 82.49% of US stocks.
  • The strongest trend for ZSAN is in Stability, which has been heading up over the past 164 days.
  • ZSAN's current lowest rank is in the Quality metric (where it is better than 1% of US stocks).

ZSAN Stock Summary

  • Zosano Pharma Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.13% of US listed stocks.
  • ZSAN's price/sales ratio is 55.84; that's higher than the P/S ratio of 96.61% of US stocks.
  • Revenue growth over the past 12 months for Zosano Pharma Corp comes in at 91.29%, a number that bests 92.61% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Zosano Pharma Corp are GNCA, INFI, ATNM, ARAV, and VBLT.
  • ZSAN's SEC filings can be seen here. And to visit Zosano Pharma Corp's official web site, go to www.zosanopharma.com.

ZSAN Valuation Summary

  • In comparison to the median Healthcare stock, ZSAN's price/earnings ratio is 107.12% lower, now standing at -2.6.
  • Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.
  • Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.

Below are key valuation metrics over time for ZSAN.

Stock Date P/S P/B P/E EV/EBIT
ZSAN 2021-08-31 121.9 1.9 -2.6 -2.3
ZSAN 2021-08-30 116.4 1.8 -2.5 -2.2
ZSAN 2021-08-27 120.6 1.9 -2.6 -2.3
ZSAN 2021-08-26 120.4 1.9 -2.6 -2.3
ZSAN 2021-08-25 118.1 1.8 -2.5 -2.3
ZSAN 2021-08-24 116.1 1.8 -2.5 -2.2

ZSAN Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -21.57%.
  • The 4 year cash and equivalents growth rate now stands at 188.24%.
  • Its 4 year net income to common stockholders growth rate is now at -15.31%.
ZSAN's revenue has moved up $922,000 over the prior 15 months.

The table below shows ZSAN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.922 -28.041 -31.052
2021-06-30 0.67 -30.719 -31.071
2021-03-31 0.482 -30.734 -32.822
2020-12-31 0.224 -31.718 -33.369
2020-09-30 0 -32.903 -34.211
2020-06-30 0 -32.646 -35.387

ZSAN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZSAN has a Quality Grade of F, ranking ahead of 0.35% of graded US stocks.
  • ZSAN's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
  • HGEN, ATRA, and ARMP are the stocks whose asset turnover ratios are most correlated with ZSAN.

The table below shows ZSAN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 0.201 -0.773
2021-03-31 0.007 0.309 -0.821
2020-12-31 0.004 0.237 -0.872
2020-09-30 0.000 NA -0.932
2020-06-30 0.000 NA -1.021
2020-03-31 0.000 NA -1.122

ZSAN Price Target

For more insight on analysts targets of ZSAN, see our ZSAN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.17 Average Broker Recommendation 1.33 (Strong Buy)

ZSAN Stock Price Chart Interactive Chart >

Price chart for ZSAN

ZSAN Price/Volume Stats

Current price $0.42 52-week high $3.06
Prev. close $0.43 52-week low $0.41
Day low $0.41 Volume 831,093
Day high $0.45 Avg. volume 2,102,384
50-day MA $0.54 Dividend yield N/A
200-day MA $0.71 Market Cap 49.71M

Zosano Pharma Corporation (ZSAN) Company Bio


Zosano Pharma Corporation provides biopharmaceutical products and services. The Company specializes in biopharmaceuticals, peptides, small water soluble molecules, monoclonal antibodies, and vaccines for the treatment of severe osteoporosis.


ZSAN Latest News Stream


Event/Time News Detail
Loading, please wait...

ZSAN Latest Social Stream


Loading social stream, please wait...

View Full ZSAN Social Stream

Latest ZSAN News From Around the Web

Below are the latest news stories about Zosano Pharma Corp that investors may wish to consider to help them evaluate ZSAN as an investment opportunity.

Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ...

Investment company Morgan Jess S & Co Inc (Current Portfolio) buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Microsoft Corp, Vanguard Total International Stock, sells Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Morgan Jess S & Co Inc.

Yahoo | January 27, 2022

CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms. The measurements of the vaccine should have been 10μg and 15μg, not 10 g and 15 g as previously stated. The corrected release follows: Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today

Yahoo | January 5, 2022

Zosano Pharma Announces Publication Of Early Data On Influenza Vaccine

Zosano Pharma Corporation (NASDAQ: ZSAN) announced the publication of Phase 1 trial data of influenza vaccine in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels and was generally well tolerated. The Company noted that a lower dose of an influenza vaccine produced antibody levels similar to an intramuscular injection of the same vaccine at a higher dose. The

Yahoo | January 5, 2022

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System” in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent i

Yahoo | January 5, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back to a new year, investor!

William White on InvestorPlace | January 3, 2022

Read More 'ZSAN' Stories Here

ZSAN Price Returns

1-mo -12.95%
3-mo -30.57%
6-mo -44.74%
1-year -55.09%
3-year -82.64%
5-year -98.16%
YTD -10.64%
2021 -10.83%
2020 -65.32%
2019 -28.30%
2018 -79.62%
2017 -33.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8995 seconds.